HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Velloso, L. M. Articles by Achour, A. Search for Related Content PubMed PubMed Citation Articles by Velloso, L. M. Articles by Achour, A. Pubmed/NCBI databases Protein Structure Compound via MeSH Substance via MeSH Hazardous Substances DB (L)-PHENYLALANINE L-TYROSINE

Determination of Structural Principles Underlying Three Different Modes of Lymphocytic Choriomeningitis Virus Escape from CTL Recognition¹

Lucas Malard Velloso^*, Jakob Michaëlsson, Hans-Gustaf Ljunggren, Gunter Schneider^* and Adnane Achour^2,

^* Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden; Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA 94141; and Center for Infectious Medicine, Department of Medicine, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden

Lymphocytic choriomeningitis virus infection of H-2^b mice generates a strong CD8⁺ CTL response mainly directed toward three immunodominant epitopes, one of which, gp33, is presented by both H-2D^b and H-2K^b MHC class I molecules. This CTL response acts as a selective agent for the emergence of viral escape variants. These variants generate altered peptide ligands (APLs) that, when presented by class I MHC molecules, antagonize CTL recognition and ultimately allow the virus to evade the cellular immune response. The emergence of APLs of the gp33 epitope is particularly advantageous for LCMV, as it allows viral escape in the context of both H-2D^b and H-2K^b MHC class I molecules. We have determined crystal structures of three different APLs of gp33 in complex with both H-2D^b and H-2K^b. Comparison between these APL/MHC structures and those of the index gp33 peptide/MHC reveals the structural basis for three different strategies used by LCMV viral escape mutations: 1) conformational changes in peptide and MHC residues that are potential TCR contacts, 2) impairment of APL binding to the MHC peptide binding cleft, and 3) introduction of subtle changes at the TCR/pMHC interface, such as the removal of a single hydroxyl group.

This article has been cited by other articles:

				L. L. Hardy, D. A. Wick, and J. R. Webb Conversion of Tyrosine to the Inflammation-Associated Analog 3'-Nitrotyrosine at Either TCR- or MHC-Contact Positions Can Profoundly Affect Recognition of the MHC Class I-Restricted Epitope of Lymphocytic Choriomeningitis Virus Glycoprotein 33 by CD8 T Cells J. Immunol., May 1, 2008; 180(9): 5956 - 5962. [Abstract] [Full Text] [PDF]

				G. S. Angelov, P. Guillaume, M. Cebecauer, G. Bosshard, D. Dojcinovic, P. Baumgaertner, and I. F. Luescher Soluble MHC-Peptide Complexes Containing Long Rigid Linkers Abolish CTL-Mediated Cytotoxicity J. Immunol., March 15, 2006; 176(6): 3356 - 3365. [Abstract] [Full Text] [PDF]

				T. Sandalova, J. Michaelsson, R. A. Harris, J. Odeberg, G. Schneider, K. Karre, and A. Achour A Structural Basis for CD8+ T Cell-dependent Recognition of Non-homologous Peptide Ligands: IMPLICATIONS FOR MOLECULAR MIMICRY IN AUTOREACTIVITY J. Biol. Chem., July 22, 2005; 280(29): 27069 - 27075. [Abstract] [Full Text] [PDF]

				M. Cebecauer, P. Guillaume, S. Mark, O. Michielin, N. Boucheron, M. Bezard, B. H. Meyer, J.-M. Segura, H. Vogel, and I. F. Luescher CD8+ Cytotoxic T Lymphocyte Activation by Soluble Major Histocompatibility Complex-Peptide Dimers J. Biol. Chem., June 24, 2005; 280(25): 23820 - 23828. [Abstract] [Full Text] [PDF]

				J.-L. Chen, G. Stewart-Jones, G. Bossi, N. M. Lissin, L. Wooldridge, E. M. L. Choi, G. Held, P. R. Dunbar, R. M. Esnouf, M. Sami, et al. Structural and kinetic basis for heightened immunogenicity of T cell vaccines J. Exp. Med., April 18, 2005; 201(8): 1243 - 1255. [Abstract] [Full Text] [PDF]